牛牛AI助理已提取核心訊息
Vertex Pharmaceuticals Inc. officer Ourania Tatsis is set to sell 360 common shares of the company on 02/21/2024, as per the latest filing. The shares, valued at an aggregate market value of $151,837.20, were acquired on 02/20/2024 as performance shares, a form of compensation from the issuer. This transaction follows a recent history of sales by Tatsis, who sold 794 shares over the past three months, generating total gross proceeds of $333,934.56. The planned sale is in line with a notice dated 02/21/2024, with the plan adopted on 05/09/2023.
Vertex Pharmaceuticals Inc. officer Ourania Tatsis is set to sell 360 common shares of the company on 02/21/2024, as per the latest filing. The shares, valued at an aggregate market value of $151,837.20, were acquired on 02/20/2024 as performance shares, a form of compensation from the issuer. This transaction follows a recent history of sales by Tatsis, who sold 794 shares over the past three months, generating total gross proceeds of $333,934.56. The planned sale is in line with a notice dated 02/21/2024, with the plan adopted on 05/09/2023.
最新文件顯示，Vertex Pharmicals Inc.高管歐拉尼亞·塔西斯定於2024年2月21日出售該公司的360股普通股。這些股票的總市值爲151,837.20美元，於2024年2月20日作爲績效股票收購，這是發行人的一種補償。該交易遵循了塔西斯最近的銷售歷史，塔西斯在過去三個月中出售了794股股票，總收益爲333,934.56美元。計劃中的出售與2024年2月21日的通知一致，該計劃於2023年9月5日通過。
最新文件顯示，Vertex Pharmicals Inc.高管歐拉尼亞·塔西斯定於2024年2月21日出售該公司的360股普通股。這些股票的總市值爲151,837.20美元，於2024年2月20日作爲績效股票收購，這是發行人的一種補償。該交易遵循了塔西斯最近的銷售歷史，塔西斯在過去三個月中出售了794股股票，總收益爲333,934.56美元。計劃中的出售與2024年2月21日的通知一致，該計劃於2023年9月5日通過。
有用
沒用
該公告為獨立文件：